**4.2. Antibiotic therapy**

Antibiotic regimens of carbapenem-resistant bacillary pneumonia often rely only on few antibiotics. Although there is not an ideal therapeutic regimen for the treatment of pneumonia due to carbapenem-resistant species, Polymixin B, Tigecycline, and Amikacine remain the most valid options [28]. A prerequisite for adequate treatment of VAPs is intravenous administration of the suitable antibiotic. Aerosolized antibiotics delivery has been experimentally studied in order to reduce the side effects of systemic administration of antibiotics. Efficiency of these methods relies on the antibiotics' ability on crossing the alveolar-capillary membrane [29]. An abundant literature is devoted to the issue of carbapenem-resistant strains. Because antibiotic resistance continuously evolved, clinical guidelines rapidly changed, therefore, a unique treatment scheme is almost impossible to establish. Clearly, we must look at the information provided by extensive epidemiological studies to up-date infection control and treatment options [30].
